Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients.

Literature DB >> 15650005

Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients.

F Canta, R Marrone, S Bonora, A D'Avolio, M Sciandra, A Sinicco, F G De Rosa, G Di Perri.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2005 PMID： 15650005 DOI： 10.1093/jac/dkh516

Source DB: PubMed Journal: J Antimicrob Chemother ISSN： 0305-7453 Impact factor: 5.790

Keyword Cloud
Cited

× No keyword cloud information.

16 in total

1. Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patients.

Authors: Leonardo Calza; Laura Mosca; Daria Pocaterra; Benedetta Piergentili; Vincenzo Colangeli; Roberto Manfredi; Annalisa Erario; Gabriele Grossi; Gabriella Verucchi; Pierluigi Viale
Journal: Eur J Clin Pharmacol Date: 2010-09-28 Impact factor: 2.953

2. Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosis.

Authors: José Moltó; Marta Valle; Asunción Blanco; Eugenia Negredo; Meritxell DelaVarga; Cristina Miranda; José Miranda; Pere Domingo; Josep Vilaró; Cristina Tural; Joan Costa; Manuel José Barbanoj; Bonaventura Clotet
Journal: Clin Pharmacokinet Date: 2007 Impact factor: 6.447

3. Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness.

Authors: J Cusato; S Allegra; D Massano; S De Francia; A Piga; A D'Avolio
Journal: Pharmacogenomics J Date: 2014-10-28 Impact factor: 3.550

4. Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitor regimens.

Authors: Amedeo De Nicolò; Marco Simiele; Andrea Calcagno; Adnan Mohamed Abdi; Stefano Bonora; Giovanni Di Perri; Antonio D'Avolio
Journal: Antimicrob Agents Chemother Date: 2014-05-05 Impact factor: 5.191

5. Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis.

Authors: Valeria Micheli; Mario Regazzi; Laura Dickinson; Paola Meraviglia; Paola Villani; Saye H Khoo; Paolo Viganò; Laura Cordier; Maria Cusato; Piergiorgio Duca; Giovanna Orlando; Giuliano Rizzardini; David J Back; Antonietta Cargnel
Journal: Ther Drug Monit Date: 2008-06 Impact factor: 3.681

Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients.

1. Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patients.

2. Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosis.

3. Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness.

4. Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitor regimens.

5. Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis.

Review 6. Antiretroviral therapy : pharmacokinetic considerations in patients with renal or hepatic impairment.

7. Disrupted ER-to-Golgi Trafficking Underlies Anti-HIV Drugs and Alcohol-Induced Cellular Stress and Hepatic Injury.

Review 8. The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19.

Review 9. Hepatotoxicity of Contemporary Antiretroviral Drugs: A Review and Evaluation of Published Clinical Data.

Review 10. Current and New Drugs for COVID-19 Treatment and Its Effects on the Liver.